Clinical features
| Feature . | Value . |
|---|---|
| Sex | |
| Male, n (%) | 4 (80) |
| Female, n (%) | 1 (20) |
| Age, y | |
| Range | 55-74 |
| Mean | 60 |
| Cutaneous involvement | |
| Solitary, n (%) | 0 (0) |
| Multiple, n (%) | 5 (100) |
| Distribution | |
| Extremities, n (%) | 5 (100) |
| Trunk, n (%) | 3 (60) |
| Head and neck, n (%) | 1 (20) |
| Macroscopy | |
| Papule, n (%) | 0 (0) |
| Erythema, n (%) | 4 (80) |
| Nodules, n (%) | 5 (100) |
| Ulceration, n (%) | 2 (40) |
| Extracutaneous lesions | |
| None, n (%) | 2 (40) |
| Upper digestive tract, n (%) | 2 (40) |
| Lymphadenopathy, n (%) | 1 (20) |
| Bone marrow involvement, n (%) | 0 (0) |
| Visceral involvement, n (%) | 1 (20) |
| Clinical manifestation | |
| B symptom, n (%) | 2 (40) |
| Decreased WBC count, n (%) | 2 (40) |
| Lymphocytosis, n (%) | 0 (0) |
| Increased LDH level, n (%) | 2 (40) |
| Staging | |
| I-II, n (%) | 3 (60) |
| III-IV, n (%) | 2 (40) |
| ECOG performance status | |
| 0-1, n (%) | 2 (40) |
| 2-5, n (%) | 3 (60) |
| IPI | |
| 0-2, n (%) | 2 (40) |
| 3-5, n (%) | 3 (60) |
| Treatment | |
| Combined, n (%) | 2 (40) |
| Chemotherapy only, n (%) | 3 (60) |
| Radiotherapy only, n (%) | 0 (0) |
| Follow-up | |
| Dead, n (%) [mean survival time, mo] | 5 (100) [13] |
| Feature . | Value . |
|---|---|
| Sex | |
| Male, n (%) | 4 (80) |
| Female, n (%) | 1 (20) |
| Age, y | |
| Range | 55-74 |
| Mean | 60 |
| Cutaneous involvement | |
| Solitary, n (%) | 0 (0) |
| Multiple, n (%) | 5 (100) |
| Distribution | |
| Extremities, n (%) | 5 (100) |
| Trunk, n (%) | 3 (60) |
| Head and neck, n (%) | 1 (20) |
| Macroscopy | |
| Papule, n (%) | 0 (0) |
| Erythema, n (%) | 4 (80) |
| Nodules, n (%) | 5 (100) |
| Ulceration, n (%) | 2 (40) |
| Extracutaneous lesions | |
| None, n (%) | 2 (40) |
| Upper digestive tract, n (%) | 2 (40) |
| Lymphadenopathy, n (%) | 1 (20) |
| Bone marrow involvement, n (%) | 0 (0) |
| Visceral involvement, n (%) | 1 (20) |
| Clinical manifestation | |
| B symptom, n (%) | 2 (40) |
| Decreased WBC count, n (%) | 2 (40) |
| Lymphocytosis, n (%) | 0 (0) |
| Increased LDH level, n (%) | 2 (40) |
| Staging | |
| I-II, n (%) | 3 (60) |
| III-IV, n (%) | 2 (40) |
| ECOG performance status | |
| 0-1, n (%) | 2 (40) |
| 2-5, n (%) | 3 (60) |
| IPI | |
| 0-2, n (%) | 2 (40) |
| 3-5, n (%) | 3 (60) |
| Treatment | |
| Combined, n (%) | 2 (40) |
| Chemotherapy only, n (%) | 3 (60) |
| Radiotherapy only, n (%) | 0 (0) |
| Follow-up | |
| Dead, n (%) [mean survival time, mo] | 5 (100) [13] |
WBC indicates white blood cell; LDH, serum lactic dehydrogenase; ECOG, Eastern Cooperative Oncology Group; and IPI, International Prognostic Index.